Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.11
-0.12 (-0.70%)
At close: Jun 27, 2025, 4:00 PM
17.25
+0.14 (0.82%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
$1,627,821
Profits / Employee
-$181,041
Market Cap
1.68B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,372 | 58 | 4.41% |
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
SRPT News
- 1 day ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) - GlobeNewsWire
- 2 days ago - Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Sarepta Therapeutics, Inc. Securities and Sets a Lead Plaintiff Deadline of August 25, 2025 - GlobeNewsWire
- 2 days ago - SRPT SECURITIES: Lose Money on Sarepta Therapeutics, Inc. (NASDAQ:SRPT)? Contact BFA Law about the Pending Securities Fraud Investigation - GlobeNewsWire
- 3 days ago - Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny - Benzinga
- 4 days ago - FDA investigates patient deaths after treatment with Sarepta's gene therapy - Reuters
- 4 days ago - SRPT STOCK LOSS: Sarepta Therapeutics, Inc. Shareholders are Alerted of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT) - GlobeNewsWire
- 8 days ago - Analyst Downgrades Sarepta As Elevidys Safety Clouds Future Demand - Benzinga
- 8 days ago - SRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT) - GlobeNewsWire